Dr. Machineni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Fleischer Institute Medical Weight Center
1180 Morris Park Avenue
Bronx, NY 10461Phone+1 866-633-8255
Summary
- Dr. Sriram Machineni is an Obesity Medicine Specialist in Bronx, NY. He received his medical degree from All India Institute of Medical Sciences, and completed his residency and chief residency in Internal Medicine at the University at Buffalo. He did his fellowship in Obesity Medicine from Massachusetts General Hospital/ Harvard Medical School and has been in practice 20 years. He specializes in obesity medicine & nutrition and is experienced in post-bariatric complications. He conducts clinical research in obesity treatment and is passionate about educating medical students, residents, fellows and peer physicians in the management of obesity. He has 20 publications and over 500 citings.
Education & Training
- Harvard Medical SchoolObesity Medicine, Clinical and Research Fellowship, 2010 - 2013
- University at BuffaloResidency, Internal Medicine, 1999 - 2003
- All India Institute of Medical SciencesClass of 1998
Certifications & Licensure
- NY State Medical License 2003 - 2026
- NC State Medical License 2017 - 2023
- MA State Medical License 2008 - 2019
- ME State Medical License Active through 2011
- American Board of Internal Medicine Internal Medicine
- American Board of Obesity Medicine Obesity Medicine
Publications & Presentations
PubMed
- 72 citationsTirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.Thomas A Wadden, Ariana M Chao, Sriram Machineni, Robert Kushner, Jamy Ard
Nature Medicine. 2023-11-01 - 25 citationsChanges in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.Leigh Perreault, Melanie Davies, Juan P Frias, Peter Nørkjaer Laursen, Ildiko Lingvay
Diabetes Care. 2022-10-01 - 8 citationsEffect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19.Lindsey Rosman, Tiffany Armbruster, Sayyad Kyazimzade, Zachary Tugaoen, Anthony J. Mazzella
Pacing and Clinical Electrophysiology. 2021-02-10
Press Mentions
- Continuous Glucose Monitoring Might Help in Managing Postoperative HypoglycemiaJuly 28th, 2023
- For First Time Since 2014, FDA Approves New Drug for Chronic Weight ManagementJune 7th, 2021
- Newly Approved Drug Heralded as 'Game Changer' in the Growing National Obesity CrisisJune 4th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: